Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472196 | 0.85 | TRPM8 (0.53) | MAPTTRPM8GAAKMT2ASMN1; SMN2 | |
| SCHEMBL3868528 | 0.83 | PTGS2 (0.55) | MAPTTRPM8RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2795176 | 0.83 | POLB (0.58) | MAPTKMT2ASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL4842036 | 0.83 | SMN1; SMN2 (0.63) | TRPM8NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3864570 | 0.78 | PTGS2 (0.59) | MAPTGAAKMT2ASMN1; SMN2LMNA | |
| SCHEMBL8549681 | 0.78 | KMT2A (0.62) | MAPTRAB9AKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL257484 | 0.78 | KDM4E (0.50) | MAPTNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17243787 | 0.76 | POLB (0.47) | MAPTGAAKMT2AKDM4ELMNA | |
| SCHEMBL4422091 | 0.76 | MAOB (0.61) | SMN1; SMN2 | |
| SCHEMBL1399311 | 0.76 | TDP1 (0.56) | NPC1RAB9AGAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| EP-1472209-B1 | LIPOXIN A4 ANALOGS | BAYER SCHERING PHARMA AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-6831186-B2 | Antiinflammatory agents; autoimmune disease | SCHERING AKTIENGESELLSCHFT (DE) | 2004-12-14 | — | — | US | disclosed |
| EP-1472209-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040162433-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | US | disclosed |
| US-20030139376-A1 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003040080-A2 | LIPOXIN A4 ANALOGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037864-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTA4H | MAPT 4880/4885TRPM8 3295/4885NPC1 3416/4885 |
| US-20040162433-A1 | Lipoxin A4 analogs | LTA4H, LTB4R, LTB4R2 | MAPT 4876/4885TRPM8 3746/4885NPC1 3420/4885 |
| US-20030139376-A1 | Lipoxin A4 analogs | LTA4H, LTB4R, LTB4R2 | MAPT 4876/4885TRPM8 3746/4885NPC1 3420/4885 |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTC4S | MAPT 4879/4885TRPM8 3355/4885NPC1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.